Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Carol Zielike

Family Medicine Rapid City, SD Medical Doctor

NPI 1851347561 CMS profile 356030

717 Saint Francis St, Rapid City, SD 57701

Open in the dashboard

General payments

$1,620

136 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Carol Zielike of Rapid City, SD is reported in the CMS Open Payments database as having received $1,620 across 136 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $83 4
2021 General $491 32
2020 General $94 8
2019 General $951 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carol Zielike
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Carol Zielike were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Carol Zielike Family Medicine median Middle half National median
2019 $951 $150 $41–$543 $163
2020 $94 $120 $32–$415 $114
2021 $491 $137 $35–$551 $132
2022 $83 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Amgen Inc. $221 19 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $175 17 payments
  3. Merck Sharp & Dohme Corporation $171 20 payments
  4. AstraZeneca Pharmaceuticals LP $149 2 payments
  5. Pfizer Inc. $149 18 payments
  6. GlaxoSmithKline, LLC. $132 15 payments
  7. Novo Nordisk Inc $112 7 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $89 9 payments
  9. Janssen Pharmaceuticals, Inc $84 5 payments
  10. Lilly USA, LLC $81 6 payments
  11. Other $258 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,620 136 payments
Products named General payments · program years 2019–2022
  1. FARXIGA $149 2 payments
  2. Prolia $139 12 payments
  3. JARDIANCE $136 12 payments
  4. SYMBICORT $135 1 payment
  5. BEVESPI AEROSPHERE $135 1 payment
  6. EVENITY $119 10 payments
  7. JANUVIA $106 11 payments
  8. JANUMET $96 10 payments
  9. CHANTIX $95 12 payments
  10. Repatha $88 8 payments
  11. Other $1,935 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record